Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study.

Anemia related to adjuvant chemotherapy might predict compromised survival in patients with breast cancer. The present population-based study was to investigate the correlation of pretreatment anemia with pathological response and long-term prognosis of breast cancer patients receiving neoadjuvant c...

Full description

Bibliographic Details
Main Authors: Wenjie Zhu, Binghe Xu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4546363?pdf=render
_version_ 1828492247276978176
author Wenjie Zhu
Binghe Xu
author_facet Wenjie Zhu
Binghe Xu
author_sort Wenjie Zhu
collection DOAJ
description Anemia related to adjuvant chemotherapy might predict compromised survival in patients with breast cancer. The present population-based study was to investigate the correlation of pretreatment anemia with pathological response and long-term prognosis of breast cancer patients receiving neoadjuvant chemotherapy (NCT).From 1999 to 2011, a total of 655 patients with operable or locally advanced breast cancer who underwent NCT before definitive surgery were reviewed. The patients were subdivided into anemic (baseline hemoglobin (Hb)<12.0 g/dL) and non-anemic (Hb≥12.0 g/dL) groups. Comparison was made between anemic and non-anemic groups concerning the rate of pathological complete response (pCR), relapse-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS). Logistic and Cox regression models were utilized to determine the predictive value of pretreatment anemia in outcomes of patients undergoing NCT.166 women (25.3%) were anemic before treatment. Patients in the anemic group were less likely to achieve pCR in NCT than their non-anemic counterparts (odds ratio (OR) 0.428, 95% confidence interval (CI) 0.198-0.927, p = 0.031). Patients with baseline anemia displayed inferior 10-year RFS (59.1% vs 66.0%, p = 0.022 by log-rank), OS (75.3% vs 90.9%, p<0.001) and CSS (82.4% vs 94.4%, p<0.001) compared with those without. After adjustment for confounders, pretreatment anemia was demonstrated to correlate with elevated risk of relapse (hazard ratio (HR) 1.453, 95% CI 1.077-1.962, p = 0.015), cancer-specific mortality (HR 2.961, 95% CI 1.679-5.222, p<0.001) and all-cause mortality (HR 2.873, 95% CI 1.757-4.699, p<0.001).Pretreatment anemia was associated with worse pathological response to NCT as well as survival status in breast cancer. Further studies are warranted to identify optimal interventions and improve the prognosis of this subgroup.
first_indexed 2024-12-11T11:17:01Z
format Article
id doaj.art-63f00ceae1fe4c1187236cd9205bedc0
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-11T11:17:01Z
publishDate 2015-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-63f00ceae1fe4c1187236cd9205bedc02022-12-22T01:09:17ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01108e013626810.1371/journal.pone.0136268Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study.Wenjie ZhuBinghe XuAnemia related to adjuvant chemotherapy might predict compromised survival in patients with breast cancer. The present population-based study was to investigate the correlation of pretreatment anemia with pathological response and long-term prognosis of breast cancer patients receiving neoadjuvant chemotherapy (NCT).From 1999 to 2011, a total of 655 patients with operable or locally advanced breast cancer who underwent NCT before definitive surgery were reviewed. The patients were subdivided into anemic (baseline hemoglobin (Hb)<12.0 g/dL) and non-anemic (Hb≥12.0 g/dL) groups. Comparison was made between anemic and non-anemic groups concerning the rate of pathological complete response (pCR), relapse-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS). Logistic and Cox regression models were utilized to determine the predictive value of pretreatment anemia in outcomes of patients undergoing NCT.166 women (25.3%) were anemic before treatment. Patients in the anemic group were less likely to achieve pCR in NCT than their non-anemic counterparts (odds ratio (OR) 0.428, 95% confidence interval (CI) 0.198-0.927, p = 0.031). Patients with baseline anemia displayed inferior 10-year RFS (59.1% vs 66.0%, p = 0.022 by log-rank), OS (75.3% vs 90.9%, p<0.001) and CSS (82.4% vs 94.4%, p<0.001) compared with those without. After adjustment for confounders, pretreatment anemia was demonstrated to correlate with elevated risk of relapse (hazard ratio (HR) 1.453, 95% CI 1.077-1.962, p = 0.015), cancer-specific mortality (HR 2.961, 95% CI 1.679-5.222, p<0.001) and all-cause mortality (HR 2.873, 95% CI 1.757-4.699, p<0.001).Pretreatment anemia was associated with worse pathological response to NCT as well as survival status in breast cancer. Further studies are warranted to identify optimal interventions and improve the prognosis of this subgroup.http://europepmc.org/articles/PMC4546363?pdf=render
spellingShingle Wenjie Zhu
Binghe Xu
Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study.
PLoS ONE
title Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study.
title_full Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study.
title_fullStr Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study.
title_full_unstemmed Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study.
title_short Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study.
title_sort association of pretreatment anemia with pathological response and survival of breast cancer patients treated with neoadjuvant chemotherapy a population based study
url http://europepmc.org/articles/PMC4546363?pdf=render
work_keys_str_mv AT wenjiezhu associationofpretreatmentanemiawithpathologicalresponseandsurvivalofbreastcancerpatientstreatedwithneoadjuvantchemotherapyapopulationbasedstudy
AT binghexu associationofpretreatmentanemiawithpathologicalresponseandsurvivalofbreastcancerpatientstreatedwithneoadjuvantchemotherapyapopulationbasedstudy